IL-13 Receptor-Targeted Therapies in Glioblastoma
Summary
Glioblastoma (GBM) remains among the most lethal brain tumours, in part due to its diffuse infiltration, molecular heterogeneity and the protective effect of the blood–brain barrier. Interleukin-13 receptor alpha 2 (IL-13Rα2) has emerged as a compelling target: it is highly overexpressed on the surface of the majority of GBM cells yet minimally present on normal neural tissue. Therapeutic strategies directed at IL-13Rα2 span a spectrum from engineered cytotoxins and receptor-targeted radionuclides to antibody–drug conjugates, cellular immunotherapies and nanotechnology-enabled drug delivery systems. By harnessing the selective binding of IL-13 or IL-13-derived ligands, these approaches aim to deliver potent anti-tumour agents directly to malignant cells, minimising off-target effects. Convection-enhanced delivery and blood–brain barrier-penetrating nanocarriers further enhance local drug concentration. Preclinical studies demonstrate that IL-13Rα2-targeted therapies can induce DNA double-strand breaks, suppress proliferation markers and extend survival in orthotopic GBM models. As combination regimens and multi-receptor targeting gain traction, IL-13Rα2-directed treatments hold promise to address intratumoural diversity and therapeutic resistance.
Research from Nature Portfolio
No recent Nature Portfolio content available.
IL-13 Receptor-Targeted Therapies in Glioblastoma publication trend
The graph below shows the total number of articles in il-13 receptor-targeted therapies in glioblastoma across all publications each year (not limited to Nature Index journals).
Technical terms
IL-13Rα2: A subtype of the interleukin-13 receptor overexpressed on glioblastoma cells but largely absent in normal brain tissue, making it a selective therapeutic target.
Glioblastoma (GBM): The most aggressive primary brain tumour in adults, characterised by rapid progression, heterogeneity and resistance to standard therapies.
Convection-enhanced delivery (CED): A technique that infuses therapeutic agents directly into brain tissue under continuous positive pressure, bypassing the blood–brain barrier and enhancing local concentration.
Alpha particle therapy: A form of targeted radiotherapy utilising alpha-emitting isotopes to deliver high-energy radiation over a short range, causing lethal DNA damage to cancer cells while sparing surrounding tissue.
Nanocarrier: A nanoscale vehicle designed to encapsulate and transport drugs or imaging agents across biological barriers, such as the blood–brain barrier, and to deliver them selectively to tumour cells.
References
- Expression of Interleukin-13 Receptor Alpha 2 in Brainstem Gliomas. Cancers (2024).
- IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget (2017).
- Receptor-Targeted Glial Brain Tumor Therapies. International Journal of Molecular Sciences (2018).
- Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers. Drug Delivery (2022).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.